26Vote!
Red Orbit (Free subscription) | yesterday
The National Institute for Health and Clinical Excellence has recommended Novartis's Lucentis as a cost-effective therapy for all eligible patients with wet age-related macular degeneration.
+Vote!
Business Wire (Free subscription) | yesterday
Research and Markets: The Top 10 World's Leading Pharmaceutical Companies: Novartis Available Now for Review DUBLIN, Ireland--()--Research and Markets () has announced the addition of the "The Top 10 World's Leading Pharmaceutical Companies: Novartis" report to their offering. In a highly dynamic and fragmented pharmaceutical market, besieged by intense competition, rapid pace of technological innovations...
+Vote!
Inbox Robot: Swiss Reinsurance News (Free subscription) | yesterday
NexMed Shares Sink on Novartis Decision Aug. 28, 2008 | Vol. 5 No. 169 Drug developer NexMed Inc. said that its development partner, Swiss drug maker ...
+Vote!
Fiercebiotech (Free subscription) | 27/08/2008
Shares of NexMed tanked after the company announced late Tuesday that Novartis would not be submitting an NDA for their partnered nail fungus therapy "at this time." According to NexMed, Novartis was persuaded to pull back after considering the results of late-stage studies. NexMed's stock quickly nosedived, losing 96 cents--or a little more than 70 percent of its value. Novartis took control of the...
+Vote!
Inbox Robot: Swiss Reinsurance News (Free subscription) | 27/08/2008
ZURICH, Aug 27 (Reuters) - Novartis's (NOVN.VX: ) Glivec has received U.S. regulator priority review as the first therapy to reduce the recurrence of ...
+Vote!
Medical,Health News and Articles (Free subscription) | yesterday
Pharmaceutical News Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the [...]
+Vote!
Pharmalot (Free subscription) | 27/08/2008
…more accustomed to backing Republican candidates for president. As the Democratic Convention builds to its unsurprising crescendo, a few drugmakers have tried to generate some political capital behind the scenes. For instance, Merck, Amgen, Pfizer, AstraZeneca, Novartis, Mylan Labs, Abbott Labs and Lilly all signed up as official sponsors. And as FDA Legislative Watch notes, the [...]
+Vote!
Nature (Free subscription) | 27/08/2008
Proc. Natl Acad. Sci. USA105, 11945–11950 (2008)A compound that inhibits the production of ATP, the primary energy carrier in cells, could make treating tuberculosis a little easier, report Kevin Pethe at the Novartis Institute for Tropical Diseases in Chromos, Singapore, and his
+Vote!
Pharmalot (Free subscription) | 26/08/2008
The FDA sent a warning letter on August 12 to the drugmaker’s Sandoz generic unit about a failure to properly validate the manufacturing process for a copycat version of AstraZeneca’s Toprol XL, a blood pressure medication, which it makes a North Carolina plant. “We question the continued distribution of this product until better process controls are [...]
+Vote!
Knowledge Jolt with Jack (Free subscription) | 26/08/2008
Knowledge management has been interesting to pharmaceutical companies for a long time. In the 1990's Monsanto and Novartis were well-known for their efforts at taking advantage of the intelligence of their people to come up with the next great innovation.
+Vote!
Fiercebiotech (Free subscription) | 25/08/2008
Despite a lack of office space or even a complete research team, newcomer ProteoStasis Therapeutics has secured a whopping $45 million in Series A financing. Investors include Boston-based HealthCare Ventures, Fidelity Biosciences, New Enterprise Associates, Novartis Option Fund and Genzyme Ventures. The funds will support research and development for therapies to treat genetic, degenerative and metabolic...
+Vote!
SPICY IP (Free subscription) | 21/08/2008
In a previous post , Prashant touched upon the brazen way in which the patent manual sought to prejudge the Novartis (Glivec) case. For those of you not familiar with the Novartis patent litigation (given the 100 odd posts that we've done so far on this big ticket patent litigation in India, its highly unlikely that our readers may not have come across this till now), here is a brief gist, from a...
+Vote!
Medical News Today (Free subscription) | 20/08/2008
Researchers at Van Andel Institute (VAI) and Novartis Institutes for Biomedical Research have identified an important enzyme required for cancer cell survival. Lowering levels of the enzyme caused a wide variety of cancer cells to die, reduced proliferation of cancer cells, and sensitized cancer cells to commonly used chemotherapeutic agents, such as the drug Taxol.
+Vote!
Singapore News Alternative (Free subscription) | 19/08/2008
Guardian.co.uk 18 Aug 2008 CHICAGO, Aug 18 (Reuters) - Gen-Probe Inc said on Monday it is replacing blood testing products shipped to customers from a Novartis warehouse in Singapore after regulators found improper storage conditions at the facility. Gen-Probe said it believes Novartis, which distributes the Procleix and Procleix Ultrio blood screening assays, has sufficient inventory to prevent any...
